{"product_id":"pt-141","title":"PT-141","description":"\u003ch2\u003e\u003cb\u003ePT-141 — Melanocortin Receptor Agonist\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003ePT-141 — known generically as bremelanotide — is a synthetic cyclic heptapeptide and melanocortin receptor agonist with preferential activity at MC3R and MC4R. Researchers studying CNS-mediated sexual response, melanocortin pharmacology, and peptide candidates investigated for male sexual potential and arousal pathways source PT-141 as the most clinically validated research compound in this mechanistic class.\u003c\/p\u003e\n\u003cp\u003eStructurally, PT-141 is the active metabolite of Melanotan 2, differing only in its C-terminal carboxylic acid (vs. MT-2's amide). The substitution shifts receptor selectivity toward MC3R and MC4R while reducing MC1R engagement — meaning PT-141 retains the CNS-mediated sexual response activity of its parent compound while substantially diminishing the pigmentary effects.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₅₀H₆₈N₁₄O₁₀ \/ 1025.2 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 189691-06-3\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes PT-141 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003ePT-141 traces its origin to the University of Arizona melanocortin research program led by Victor Hruby and Mac Hadley, where structure-activity work on Melanotan 2 produced the now well-known observation that broad-spectrum melanocortin agonism engaged not only pigmentation pathways but also CNS-mediated sexual response circuitry. Palatin Technologies subsequently developed PT-141 (bremelanotide) as a more receptor-selective compound that preserved the CNS activity while attenuating peripheral melanocortin engagement.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes PT-141 in current research is its regulatory status. In June 2019, the FDA approved bremelanotide under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it the only peptide-based melanocortin agonist with full FDA clinical validation in this domain. That approval gives researchers a published Phase 3 dataset, characterized human pharmacokinetics, and a defined mechanism — properties most research peptides lack. Its action is mediated centrally via hypothalamic melanocortin receptors, distinguishing it mechanistically from peripheral vasodilator approaches to sexual dysfunction research.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eCNS-Mediated Sexual Response —\u003c\/b\u003e Animal and clinical studies have characterized PT-141's activation of hypothalamic MC3R and MC4R as the basis for downstream effects on sexual desire and arousal circuitry, distinguishing it from peripheral vasodilator compounds in mechanistic research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMelanocortin Receptor Pharmacology —\u003c\/b\u003e PT-141 serves as a reference MC3R\/MC4R-preferring agonist in receptor-deconvolution studies, frequently compared against non-selective tools like Melanotan 2 to dissect receptor-subtype contributions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAppetite \u0026amp; Energy Balance —\u003c\/b\u003e Hypothalamic MC4R activation has been studied in animal models for its role in feeding suppression, and PT-141 contributes to the published dataset on MC4R-mediated satiety signaling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePharmacokinetic Characterization —\u003c\/b\u003e As one of few melanocortin peptides with detailed published clinical pharmacokinetic data, PT-141 functions as a reference compound for groups studying cyclic-heptapeptide ADME profiles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eComparator in Sexual Function Research —\u003c\/b\u003e PT-141's centrally mediated mechanism makes it a frequently used comparator in research designs evaluating peptide-based versus small-molecule approaches to sexual response pathway investigation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with PT-141 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-melanotan-2-canada\" title=\"View Melanotin II Product Page\"\u003eMelanotan II (MT-2)\u003c\/a\u003e\u003c\/b\u003e — The non-selective parent compound from which PT-141 is derived; the standard mechanistic contrast for receptor-selectivity studies and one of the most common research pairings in the published melanocortin literature.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-tesamorelin-canada\" title=\"View Tesamorelin Product Page\"\u003eTesamorelin\u003c\/a\u003e\u003c\/b\u003e — GHRH analog acting on hypothalamic-pituitary signaling; provides a complementary mechanism for groups studying peptide-mediated CNS-endocrine pathway activity alongside melanocortin research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/ghk-cu\" title=\"View GHK-Cu Product Page\"\u003eGHK-Cu\u003c\/a\u003e\u003c\/b\u003e — Copper tripeptide investigated for skin and ECM remodeling; pairs with PT-141 in research designs spanning the skin-and-sexual-health endpoints common in melanocortin-system studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhy is PT-141 frequently described as a best peptide for male potential increase research?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePT-141 is the most clinically validated research peptide acting on CNS-mediated sexual response pathways. It engages MC3R and MC4R in hypothalamic circuits associated with sexual desire and arousal, mechanistically distinct from peripheral vasodilator compounds like PDE5 inhibitors. The compound completed Phase 3 clinical trials under the brand name Vyleesi and received FDA approval in 2019 for hypoactive sexual desire disorder. That published dataset, combined with a defined receptor-selectivity profile, places it among the most studied research peptides in male and female sexual response models.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is PT-141 different from Melanotan 2?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eBoth are cyclic heptapeptide α-MSH analogs with the same seven-amino-acid sequence. The single structural difference is at the C-terminus: PT-141 ends in a carboxylic acid (-OH), while Melanotan 2 ends in an amide (-NH₂). PT-141 is the active metabolite of Melanotan 2 in vivo. Functionally, the substitution shifts receptor selectivity toward MC3R and MC4R while reducing MC1R engagement, meaning PT-141 retains the CNS-mediated sexual response profile while showing diminished pigmentation activity compared to its parent.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs PT-141 naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eNo. PT-141 is fully synthetic, engineered as a stable cyclic analog of α-MSH, the natural 13-amino-acid melanocortin hormone. The structural modifications — D-phenylalanine substitution, norleucine for methionine, and the Asp-Lys lactam bridge — are non-natural and confer the metabolic stability that endogenous α-MSH lacks.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for PT-141?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePT-141 has one of the most developed evidence bases of any research-relevant melanocortin peptide. Phase 3 clinical trials in premenopausal women with hypoactive sexual desire disorder supported its 2019 FDA approval under the brand name Vyleesi. The preclinical literature spans more than two decades and includes published work in male and female sexual response, melanocortin receptor pharmacology, and pharmacokinetic characterization. Earlier-stage clinical work in male erectile dysfunction was also conducted, providing additional published data points.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":46052264247433,"sku":null,"price":44.99,"currency_code":"CAD","in_stock":false},{"title":"6 x 10mg","offer_id":46052264280201,"sku":null,"price":239.99,"currency_code":"CAD","in_stock":false},{"title":"10 x 10mg (one box)","offer_id":46134036332681,"sku":null,"price":399.99,"currency_code":"CAD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/pt-141-10mg-peptides-canada_standardized.png?v=1778371603","url":"https:\/\/emeraldpeptides.ca\/products\/pt-141","provider":"Emerald Peptides","version":"1.0","type":"link"}